NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF
申请人:SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.
公开号:US20190010153A1
公开(公告)日:2019-01-10
The present invention discloses a nitrogen-containing fused heterocyclic compound, as well as a preparation method, intermediate, composition and application thereof. The nitrogen-containing fused heterocyclic compound of the present invention as represented by formula (I), as well as the pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, metabolite or drug precursor thereof, exhibit a high selectivity and a high inhibitory activity with respect to CDK4 and CDK6 at a molecular level, an excellent inhibitory activity with respect to breast cancer cells at a cellular level, and significant inhibition of tumor cell proliferation associated with cyclin-dependent kinase activity at an animal level. The invention also exhibits a good stability with respect to human or mouse liver microsomes without significant inhibition of metabolic enzymes, good in vivo absorption in mice and rats, a high bioavailability and good druggability.
本发明公开了一种含氮融合杂环化合物,以及其制备方法、中间体、组合物和应用。本发明的含氮融合杂环化合物如公式(I)所示,以及其药学上可接受的盐、对映体、二对映体、互变异构体、溶剂合物、代谢物或药物前体,在分子水平上对CDK4和CDK6表现出高选择性和高抑制活性,在细胞水平上对乳腺癌细胞表现出优异的抑制活性,并在动物水平上显著抑制与细胞周期依赖性激酶活性相关的肿瘤细胞增殖。该发明还在人类或小鼠肝微粒体中表现出良好的稳定性,没有显著抑制代谢酶,对小鼠和大鼠体内吸收良好,具有高生物利用度和良好的药物可用性。